Jose Rubio-Briones
Overview
Explore the profile of Jose Rubio-Briones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mafla-Espana M, Torregrosa M, Beamud-Cortes M, Bermell-Marco L, Rubio-Briones J, Cauli O
Biomolecules
. 2023 Nov;
13(11).
PMID: 38002324
Background: Androgen deprivation therapy (ADT) is a mainstay of prostate cancer in both adjuvant and palliative settings. Since androgens are crucial for functional status and psychological functions, we evaluated whether...
2.
Beijert I, Hentschel A, Brundl J, Comperat E, Plass K, Rodriguez O, et al.
Int Urol Nephrol
. 2023 Nov;
56(4):1323-1333.
PMID: 37980689
Purpose: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial...
3.
Rossin G, Zorzi F, de Pablos-Rodriguez P, Biasatti A, Marenco J, Ongaro L, et al.
Diagnostics (Basel)
. 2023 Aug;
13(15).
PMID: 37568905
Sentinel node biopsy (SNB) for prostate cancer (PCa) represents an innovative technique aimed at improving nodal staging accuracy. The routinary adoption of this procedure in patients undergoing radical prostatectomy (RP)...
4.
de Pablos-Rodriguez P, Claps F, Rebez G, Vidal Crespo N, Gomez-Ferrer A, Mascaros J, et al.
BJU Int
. 2023 Jul;
132(5):591-599.
PMID: 37410659
Objectives: To study the safety and efficacy of a personalised indocyanine-guided pelvic lymph node dissection (PLND) against extended PLND (ePLND) during radical prostatectomy (RP). Patients And Methods: Patients who were...
5.
Mafla-Espana M, Torregrosa M, Beamud-Cortes M, Bermell-Marco L, Rubio-Briones J, Cauli O
Healthcare (Basel)
. 2023 May;
11(9).
PMID: 37174808
Background: Prostate cancer (PCa) is considered one of the most important medical problems in the male population, with a very high incidence after the age of 65. Frailty represents one...
6.
Lozano R, Castro E, Lopez-Campos F, Thorne H, Ramirez-Backhaus M, Aragon I, et al.
Eur J Cancer
. 2023 Mar;
185:105-118.
PMID: 36972661
Background: Several studies have reported the association of germline BRCA2 (gBRCA2) mutations with poor clinical outcomes in prostate cancer (PCa), but the impact of concurrent somatic events on gBRCA2 carriers...
7.
Sylvester R, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins H, et al.
Eur Urol
. 2023 Feb;
83(5):e140-e141.
PMID: 36841687
No abstract available.
8.
Borque-Fernando A, Gaya J, Esteban-Escano L, Gomez-Rivas J, Garcia-Baquero R, Agreda-Castaneda F, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765574
Introduction: Penile cancer (PC) is a rare malignancy with an overall incidence in Europe of 1/100,000 males/year. In Europe, few studies report the epidemiology, risk factors, clinical presentation, and treatment...
9.
Beijert I, Hentschel A, Brundl J, Comperat E, Plass K, Rodriguez O, et al.
Eur Urol Oncol
. 2023 Jan;
6(2):214-221.
PMID: 36670042
Background: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the...
10.
Light A, Lophatananon A, Keates A, Thankappannair V, Barrett T, Dominguez-Escrig J, et al.
J Clin Med
. 2023 Jan;
12(1).
PMID: 36615017
For men with newly diagnosed prostate cancer, we aimed to develop and validate a model to predict the risk of progression on active surveillance (AS), which could inform more personalised...